Skip to main content
26/10/2023

The Fira dels Somnis of Balaguer has raised more than 25,000 euros for VHIR's research against childhood cancer

Fira-somnis-2023

26/10/2023

The funds will enable the recruitment and retention of young talent, as well as the development of a new epigenetic drug

The seventh edition of the Fira dels Somnis of Balaguer has obtained more than 25,000 euros. All the funds will go to the Laboratory of Neural Tumours of the Research Group of Childhood Cancer and Blood Diseases of the Vall Hebron Research Institute (VHIR). Dr Miquel Segura, who leads the laboratory, explains that the funds will be used for three goals: "to attract and retain young scientists committed to the fight against childhood cancer, to promote the development of a new epigenetic drug and to acquire cutting-edge technological equipment so that scientific advances reach the patient as soon as possible". The lab specializes in tumours of the nervous system, which are one of the most common types of childhood cancer.

As every year, the Fira dels Somnis began a week before with the handrail of dreams, a space that fills the banisters of the Pont Nou with the logos of the shops, companies, and establishments that collaborate in the event. The day of the festival saw the start of the VII Cursa dels Somnis, in which more than 2,200 people took part, wearing the solidarity T-shirt, one of the main sources of funds raised by the event. Afterwards, there were talks, educational workshops given by VHIR scientists, exhibitions, magic, theatre, games, and other activities for all ages.

The success of the event has ensured the continuity of this initiative, and the organisation already has a date for the eighth edition, which will be held on 5 May 2024 in Balaguer.
 

The eighth edition will be held on 5 May 2024.

Related news

A study, co-led by Vall d’Hebron, has analysed the evolution of clinical trials with children and adolescents with cancer over the last 15 years, with the aim of optimising efficacy and defining lines for further progress.

The research team has shown that inhibiting the TRIB3 protein slows the growth of rhabdomyosarcoma and improves survival in animal models.

Vall d'Hebron presents positive results from two studies in transfusion-dependent thalassaemia and severe bone marrow aplasia at the EBMT Annual Meeting on haematopoietic stem cell transplantation.

Related professionals

Miguel Segura Ginard

Miguel Segura Ginard

Main researcher
Childhood Cancer and Blood Disorders
Read more
Aroa Soriano Fernández

Aroa Soriano Fernández

Main researcher
Childhood Cancer and Blood Disorders
Read more
Cristina  Valles  Valles

Cristina Valles Valles

Childhood Cancer and Blood Disorders
Read more
Marta Palau Requena

Marta Palau Requena

Predoctoral researcher
Childhood Cancer and Blood Disorders
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.